News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • VK2735 produced 21-week weight loss of 16–19% body weight.
  • Up to 97% of patients maintained weight loss with flexible monthly injectable dosing.
  • Viking Therapeutics shares rerated after the data release.
  • Trade idea recommends entry at $40.33.
  • Suggested stop-loss is $33.00 and target $65.00 over 180 trading days.
  • Company flagged upcoming clinical and regulatory catalysts as next milestones.

Latest Articles

Markets Tepid After Mixed Signals from Chips, Inflation and Geopolitics

Markets Tepid After Mixed Signals from Chips, Inflation and Geopolitics

Global equities and risk assets showed muted responses after uneven corporate results, cooling inflation data and renewed geopolitical tensions. Taiwan Semiconductor Manufacturing Co. delivered a surprise profit jump, but chip shares remained under pressure. Softer U.S. producer price data eased near-term rate-hike bets, yet core PCE remains above …

Twin Vee PowerCats to Merge with USFM; Shares Spike After Deal Announcement

Twin Vee PowerCats to Merge with USFM; Shares Spike After Deal Announcement

Shares of Twin Vee PowerCats Co. (NASDAQ: VEEE) jumped 28% after the company agreed to merge with private USFM Corporation, a U.S.-based mineral exploration firm focused on critical mineral targets in Greenland. The deal calls for a subsidiary of USFM to merge into Twin Vee, while Twin Vee's recreational marine operations will be spun out into a pr…

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Therapeutics has announced the addition of Sunnybrook’s Odette Cancer Centre in Toronto as the first Canadian site for its pivotal Phase 3 clinical trial evaluating Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer. The expanded trial now includes over 80 active clinical sites across the U.S. and Cana…

ZenaTech Closes 25th Acquisition with Alberta, Canada-based Velocity Geomatics Inc. Expanding Drone as a Service into Environmental and Regulatory Services in the Oil and Gas Sector

ZenaTech Closes 25th Acquisition with Alberta, Canada-based Velocity Geomatics Inc. Expanding Drone as a Service into Environmental and Regulatory Services in the Oil and Gas Sector

ZenaTech, Inc. (Nasdaq: ZENA) has acquired Velocity Geomatics Inc., a Canadian drone-based geomatics company focused on environmental and regulatory compliance services within the oil and gas industry. This marks ZenaTech's 25th acquisition as part of an aggressive expansion of its Drone as a Service (DaaS) platform, extending its presence in a rap…

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma Ltd. has received positive feedback from the FDA and central IRB approval with modifications for its optimized Phase 2 clinical trial of Teverelix®, targeting men with acute urinary retention secondary to benign prostatic hyperplasia. The redesigned study aims to enroll 126 patients, significantly fewer than the previous plan, to eff…

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Greenwich LifeSciences announced that the European Medicines Agency has approved combining both HLA-A*02 and non-HLA-A*02 breast cancer patients in the randomized arms of their Phase III FLAMINGO-01 trial evaluating GLSI-100 immunotherapy. This follows similar approval from the FDA in the US, effectively doubling enrollment capacity and statistical…

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Plus Therapeutics announces a strategic collaboration with Genomic Testing Cooperative to integrate next-generation sequencing (NGS) technology into its CNSide cerebrospinal fluid assay platform, enhancing DNA and RNA profiling capabilities for CNS cancers. This integration supports Plus' CNS oncology strategy encompassing targeted radiotherapeutic…

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma and its licensee Genevant have initiated multiple international lawsuits against Pfizer and BioNTech to enforce patents protecting their lipid nanoparticle technology used in mRNA COVID-19 vaccines. The company also received approximately $178 million from a settlement with Moderna over patent infringement, including reimbursement…

Lufthansa Group to Reinstate Flights to Riyadh and Amman This Autumn

Lufthansa Group to Reinstate Flights to Riyadh and Amman This Autumn

Lufthansa Group said it will restart routes to Riyadh and Amman following earlier suspensions of some Middle Eastern services. The group will operate flights to Riyadh from Frankfurt beginning September 10, while ITA Airways will resume Rome-Riyadh services on September 15. Austrian Airlines will restart Vienna-Amman flights on October 2. The carri…

Newmont: Permits and Project Finance Set the Table for a Re-Rating

Newmont: Permits and Project Finance Set the Table for a Re-Rating

Newmont is trading at ~12x earnings with a $101.6B market cap while advancing project funding and government-backed support that clear the path for production-extension projects. With solid free cash flow and a recently increased buyback program, the risk/reward favors a re-rating if gold fundamentals recover or project milestones catalyze multiple…

Aer Lingus Announces Up to 500 Job Cuts and 6% Capacity Reduction

Aer Lingus Announces Up to 500 Job Cuts and 6% Capacity Reduction

Aer Lingus Group DAC said it may eliminate as many as 500 positions and trim some flights as part of an organizational restructuring intended to address rising costs and stronger competition on North Atlantic routes. The carrier reduced senior management roles by roughly 25% and will cut capacity across its network by 6% from late September through…

Meta to notify parents when teens raise self-harm or suicide with Meta AI

Meta to notify parents when teens raise self-harm or suicide with Meta AI

Meta said parents using Instagram supervision tools will receive notifications if their teenager discusses suicide or self-harm with Meta AI. The company described a dedicated AI detection system, mandatory human review of flagged chats, expert resources for parents, and plans to expand the feature globally by year-end. Meta is also developing a wa…

Eli Lilly Deal Spurs Broad Rally in Psychedelic Drug Stocks

Eli Lilly Deal Spurs Broad Rally in Psychedelic Drug Stocks

Shares of companies developing psychedelic therapies jumped in premarket trading after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc. The structure of the deal and the premium paid have boosted sentiment across the sector, with several peers posting notable gains and analysts pointing to clear read-throughs for companies wit…

Paying Up for Growth: A Tactical Long on Teradyne (TER)

Paying Up for Growth: A Tactical Long on Teradyne (TER)

Teradyne trades at premium multiples - P/E in the 60s, P/S above 14 and a FCF yield near 1% - yet its business is tightening around AI-driven semiconductor test demand and robotics. With 70% of revenue tied to AI and recent reported year-over-year revenue growth near 87%, the risk-reward can favor a mid-term long if you use a strict stop and limit …